期刊文献+

Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation 被引量:4

Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation
下载PDF
导出
摘要 AIM: To evaluate the plasma von Willebrand factor (vWF) levels in patients with ulcerative colitis (UC) and to investigate their relationship with disease activity,systemic inflammation and coagulation activation.METHODS: In 46 patients with ulcerative colitis (active in 34 patients), clinical data were gathered and plasma vWF levels, markers of inflammation (ESR, CRP, and fibrinogen) and thrombin generation (TAT, F1+2, and D-dimers) were measured at baseline and after 12 wk of treatment. Plasma vWF levels were also determined in 52 healthy controls (HC). The relationship of plasma vWF levels with disease activity, disease extent, response to therapy, acute-phase reactants (APRs) and coagulation markers (COAGs) was assessed.RESULTS: The mean plasma vWF concentrations were significantly higher in active UC patients (143.38±63.73%) than in HC (100.75±29.65%, P = 0.001)and inactive UC patients (98.92±43.6%, P = 0.031).ESR, CRP and fibrinogen mean levels were significantly higher in active UC patients than in inactive UC patients,whereas there were no significant differences in plasma levels of D-dimers, F1+2, and TAT. UC patients with raised APRs had significantly higher mean plasma vWF levels than those with normal APRs (144.3% vs 96.2%,P = 0.019), regardless of disease activity. Although the mean plasma vWF levels were higher in UC patients with raised COAGs than in those with normal COAGs,irrespective of disease activity, the difference was not significant (141.3% vs 118.2%, P = 0.216). No correlation was noted between plasma vWF levels and disease extent. After 12 wk of treatment, significant decreases of fibrinogen, ESR, F1+2, D-dimers and vWF levels were noted only in UC patients with clinical and endoscopic improvement.CONCLUSION: Our data indicate that increased plasma vWF levels correlate with active ulcerative colitis and increased acute-phase proteins. Elevated plasma vWF levels in ulcerative colitis possibly reflect an acutephase response of the perturbed endothelium due to inflammation. In UC patients, plasma vWF levels may be another useful marker of disease activity or response to therapy. AIM: To evaluate the plasma von Willebrand factor (vWF) levels in patients with ulcerative colitis (UC) and to investigate their relationship with disease activity, systemic inflammation and coagulation activation.METHODS: In 46 patients with ulcerative colitis (active in 34 patients), clinical data were gathered and plasma vWF levels, markers of inflammation (ESR, CRP, and fibrinogen) and thrombin generation (TAT, F1+2, and D-dimers) were measured at baseline and after 12 wk of treatment. Plasma vWF levels were also determined in 52 healthy controls (HC). The relationship of plasma vWF levels with disease activity, disease extent, response to therapy, acute-phase reactants (APRs) and coagulation markers (COAGs) was assessed.RESULTS: The mean plasma vWF concentrations were significantly higher in active UC patients (143.38±63.73%) than in HC (100.75±29.65%, P = 0.001) and inactive UC patients (98.92±43.6%, P = 0.031). ESR, CRP and fibrinogen mean levels were significantly higher in active UC patients than in inactive UC patients, whereas there were no significant differences in plasma levels of D-dimers, F1+2, and TAT. UC patients with raised APRs had significantly higher mean plasma vWF levels than those with normal APRs (144.3% vs 96.2%, P = 0.019), regardless of disease activity. Although the mean plasma vWF levels were higher in UC patients with raised COAGs than in those with normal COAGs, irrespective of disease activity, the difference was not significant (141.3% vs 118.2%, P = 0.216). No correlation was noted between plasma vWF levels and disease extent. After 12 wk of treatment, significant decreases of fibrinogen, ESR, F1+2, D-dimers and vWF levels were noted only in UC patients with clinical and endoscopic improvement.CONCLUSION: Our data indicate that increased plasma vWF levels correlate with active ulcerative colitis and increased acute-phase proteins. Elevated plasma vWF levels in ulcerative colitis possibly reflect an acute-phase response of the perturbed endothelium due to inflammation. In UC patients, plasma vWF levels may be another useful marker of disease activity or response to therapy.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第48期7639-7645,共7页 世界胃肠病学杂志(英文版)
关键词 等离子体 肠溃疡 炎症 内皮细胞 Coagulation Endothelial injury Inflammation Inflammatory bowel disease Ulcerative colitis von Willebrand factor
  • 相关文献

参考文献1

二级参考文献10

  • 1Cui HF,Jiang XL.Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin[J].World Journal of Gastroenterology,1999,5(5):448-450. 被引量:24
  • 2Albomoz L,Alvarez D,Otaso JC,Gadano A,Salviu J,Gerona S,Sorroche P,Villamil A,Mastai R.von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis:relationship to degree of liver failure and nitric oxide levels[].Journal of Hepatology.1999
  • 3Kohno I,Inuzuka K,Itoh Y,Nakahara K,Eguchi Y,Sugo T,Soe G,Sakata Y,Murayama H,Matsuda M.A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin:its application to the measurement of granulocyte-derived elastase digests in plasma[].Blood.2000
  • 4Xu G,Zhong XJ,Guo WM,Sui RL,Tang SL,Sun YP.D-dimer and von Willebrand factor levels in acute pancreatitis patints[].World Chinese Journal of Digestology.1999
  • 5Danesh J,Whincup P,Walker M,Lermon L,Thomson A,Appleby P,Rumley A.Lowe GD: Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis[].Circulation.2001
  • 6Goldsmith I,Kumar P,Carter P,Blann AD,Patel RL,Lip GY.Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study[].American Heart Journal.2000
  • 7Jager A,van-Hinsbergh VW,Kostense PJ,Emesis JJ,Nijpels G,Dekker JM,Heine RJ,Bouter LM,Stehonwer CD.Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes:the Hoorn study[].Diabetes.2000
  • 8Feng,D,Bursell,SE,Clermont,AC.von Willebrand factor and retinal circulation in early-stage retinopathy of type 1 diabetes[].Diabetes Care.2000
  • 9Thomas K. Makris MD,George A. Stavroulakis MD,Urania G. Dafni DSc,Argyri E. Gialeraki PhD,Panagiota G. Krespi MD,Antonios N. Hatzizacharias MD,Caterina G. Tsoukala MD,John S. Vythoulkas MD and Michael K. Kyriakidis MDa,d.ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension[].American Heart Journal.2000
  • 10Kiron M. Das,Sherif A. Farag.Current medical therapy of inflammatory bowel disease[J].World Journal of Gastroenterology,2000,6(4):483-489. 被引量:16

共引文献18

同被引文献33

  • 1Sébastien Richard,Gioia Mione,Julien Perrin,Marie Toussaint-Hacquard,Jean-Christophe Lacour,Xavier Ducrocq.Internal carotid thrombus in patients with inflammatory bowel disease:Two cases[J].World Journal of Gastroenterology,2013,19(5):773-775. 被引量:1
  • 2Hitoshi Nogami,Tsuneo Iiai,Satoshi Maruyama,Tatsuo Tani,Katsuyoshi Hatakeyama.Common carotid arterial thrombosis associated with ulcerative colitis[J].World Journal of Gastroenterology,2007,13(11):1755-1757. 被引量:1
  • 3Ming Zhong,Xian Wen Dong,Qing Zheng,Jin Lu Tong,Zhi Hua Ran.Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): A meta-analysis[J].Thrombosis Research.2011(5)
  • 4Naamah L.Zitomersky,MennoVerhave,Cameron C.Trenor.Thrombosis and inflammatory bowel disease: A call for improved awareness and prevention[J].Inflamm Bowel Dis.2010(1)
  • 5Matthew J Grainge,Joe West,Timothy R Card.Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study[J].The Lancet.2010(9715)
  • 6Andrew Tinsley,Steven Naymagon,Laura M. Enomoto,Christopher S. Hollenbeak,Bruce E. Sands,Thomas A. Ullman.Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: Results from a tertiary care center[J].Journal of Crohn’s and Colitis.2013
  • 7H. Yuhara,C. Steinmaus,D. Corley,J. Koike,M. Igarashi,T. Suzuki,T. Mine.Meta‐analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease[J].Aliment Pharmacol Ther.2013(10)
  • 8Pavol Papay,Wolfgang Miehsler,Herbert Tilg,Wolfgang Petritsch,Walter Reinisch,Andreas Mayer,Thomas Haas,Arthur Kaser,Thomas Feichtenschlager,Harry Fuchssteiner,Peter Knoflach,Harald Vogelsang,Reingard Platzer,Wolfgang Tillinger,Bernhard Jaritz,Alfons Schmid,Benedikt Blaha,Clemens Dejaco,Anna Sobala,Ansgar Weltermann,Sabine Eichinger,Gottfried Novacek.Clinical presentation of venous thromboembolism in inflammatory bowel disease[J].Journal of Crohn’s and Colitis.2012
  • 9Victoria P Tan,Alvin Chung,Bryan P Yan,Peter R Gibson.Venous and arterial disease in inflammatory bowel disease[J].J Gastroenterol Hepatol.2013(7)
  • 10Julia Palkovits,Gottfried Novacek,Marietta Kollars,Gregor Hron,Wolf Osterode,Peter Quehenberger,Paul Alexander Kyrle,Harald Vogelsang,Walter Reinisch,Pavol Papay,Ansgar Weltermann.Tissue factor exposing microparticles in inflammatory bowel disease[J].Journal of Crohn’s and Colitis.2012

引证文献4

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部